E-resources
PDF-
Ariamanesh, Mona; Porouhan, Pejman; PeyroShabany, Babak; Fazilat-Panah, Danial; Dehghani, Mansoureh; Nabavifard, Maryam; Hatami, Farbod; Fereidouni, Mohammad; Welsh, James S.; Javadinia, Seyed Alireza
Cancer investigation, 01/2022, Volume: 40, Issue: 1Journal Article
To evaluate the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine in cancer patients. 364 cancer patients who received two doses of vaccine were enrolled. The presence of SARS-CoV-2 anti-Spike protein IgG and neutralizing antibody 2 months following vaccination were measured by ELIZA. Injection site pain and fever were the most common local and systemic side effects. The overall seroconversion rate was 86.9% that was lower in older age, those with hematological malignancies and chemotherapy receivers. The result of study confirmed the safety and short-term efficacy of inactivated vaccine in patients with malignancies.
